Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Net Income towards Common Stockholders: 2011-2025

Historic Net Income towards Common Stockholders for Ani Pharmaceuticals (ANIP) over the last 15 years, with Sep 2025 value amounting to $26.3 million.

  • Ani Pharmaceuticals' Net Income towards Common Stockholders rose 206.92% to $26.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.0 million, marking a year-over-year increase of 547.54%. This contributed to the annual value of -$20.1 million for FY2024, which is 217.45% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Net Income towards Common Stockholders is $26.3 million, which was up 222.68% from $8.1 million recorded in Q2 2025.
  • Over the past 5 years, Ani Pharmaceuticals' Net Income towards Common Stockholders peaked at $26.3 million during Q3 2025, and registered a low of -$24.6 million during Q3 2024.
  • Its 3-year average for Net Income towards Common Stockholders is $4.2 million, with a median of $5.8 million in 2023.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Net Income towards Common Stockholders tumbled by 25,451.85% in 2022, and later skyrocketed by 1,623.23% in 2024.
  • Ani Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at -$24.3 million in 2021, then skyrocketed by 80.88% to -$4.7 million in 2022, then soared by 116.11% to $749,000 in 2023, then slumped by 1,526.17% to -$10.7 million in 2024, then surged by 206.92% to $26.3 million in 2025.
  • Its Net Income towards Common Stockholders stands at $26.3 million for Q3 2025, versus $8.1 million for Q2 2025 and $15.3 million for Q1 2025.